News Related to CLL/SLL

Related coverage linked through entity extraction aliases.

Zanubrutinib Shows Sustained PFS Benefit at 6 Years in SEQUOIA CLL Trial

Jul 14, 2026

Six-year SEQUOIA trial data show zanubrutinib sustains a progression-free survival advantage (74% vs 32%) over bendamustine-rituximab in CLL without del(17p). Benefit extends to high-risk del(17p) patients.

FDA approves acalabrutinib plus venetoclax for first-line CLL/SLL

Apr 18, 2026

The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.